Advertisement

Rheumatology International

, Volume 29, Issue 3, pp 257–262 | Cite as

Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis

  • Jacob N. Ablin
  • Zacharinka Goldstein
  • Valerie Aloush
  • Hagit Matz
  • Ori Elkayam
  • Dan Caspi
  • Shmuel Swartzenberg
  • Jacob George
  • Yonit Wohl
Original Article

Abstract

Endothelial progenitor cells (EPCs) are a population of bone marrow derived cells which have been attributed with the ability to migrate into areas of tissue ischemia and to posses reparative qualities. EPCs have been shown to be decreased in level and function in various inflammatory disorders. Psoriasis and psoriatic arthritis are associated with an increase in cardiovascular morbidity. The aim of the study was to investigate the number of EPCs among patients suffering from psoriasis and psoriatic arthritis. Patients suffering from active psoriasis and psoriatic arthritis were recruited as well as healthy controls. Disease activity was assessed with the DAS-28, BASDAI and PASI scores. Peripheral blood mononuclear cells were isolated and EPC numbers evaluated by FACS analysis using the CD34/133 and CD34/KDR. No significant difference was found between numbers of EPCs between healthy controls, patients with psoriasis and psoriatic arthritis. A significant correlation was found between levels of VGEF and the BASDAI score. The results of the current study do not support a significant role for EPCs in the pathogenesis of psoriasis and psoriatic arthritis.

Keywords

Psoriatic arthritis Psoriasis Endothelial progenitor cells (EPCs) VGEF 

References

  1. 1.
    Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA et al (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348(7):593–600. doi: 10.1056/NEJMoa022287 PubMedCrossRefGoogle Scholar
  2. 2.
    George J, Goldstein E, Abashidze S, Deutsch V, Shmilovich H, Finkelstein A et al (2004) Circulating endothelial progenitor cells in patients with unstable angina: association with systemic inflammation. Eur Heart J 25(12):1003–1008. doi: 10.1016/j.ehj.2004.03.026 PubMedCrossRefGoogle Scholar
  3. 3.
    George J, Hertz I, Goldstein E, Abashidze S, Deutch V, Finkelstein A et al (2003) Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol 23(12):e57–e60. doi: 10.1161/01.ATV.0000107029.65274.db PubMedCrossRefGoogle Scholar
  4. 4.
    Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D et al (2005) Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111(2):204–211. doi: 10.1161/01.CIR.0000151875.21836.AE PubMedCrossRefGoogle Scholar
  5. 5.
    Ablin JN, Boguslavski V, Aloush V, Elkayam O, Paran D, Caspi D et al (2006) Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci 75(25):2364–2369. doi: 10.1016/j.lfs.2006.07.035 CrossRefGoogle Scholar
  6. 6.
    Schon MP, Boehncke W (2005) Psoriasis. N Engl J Med 352(18):1899–1912. doi: 10.1056/NEJMra041320 PubMedCrossRefGoogle Scholar
  7. 7.
    Goffe B (2004) Etanercept (Enbrel)—an update. Skin Therapy Lett 9(10):1–4PubMedGoogle Scholar
  8. 8.
    Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Etanercept Psoriasis Study Group et al (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 20(349):21Google Scholar
  9. 9.
    Mease PJ (2005) Psoriatic arthritis therapy advances. Curr Opin Rheumatol 17(4):426–432. doi: 10.1097/01.bor.0000166382.96024.85 PubMedCrossRefGoogle Scholar
  10. 10.
    Rosenzweig A (2003) Endothelial progenitor cells. N Engl J Med 348(7):581–582. doi: 10.1056/NEJMp020175 PubMedCrossRefGoogle Scholar
  11. 11.
    Ingram DA, Caplice NM, Yoder MC (2005) Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood 106(5):1525–1531. doi: 10.1182/blood-2005-04-1509 PubMedCrossRefGoogle Scholar
  12. 12.
    Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S et al (2005) Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111(18):2356–2363. doi: 10.1161/01.CIR.0000164260.82417.3F PubMedCrossRefGoogle Scholar
  13. 13.
    Dulic-Sills A, Blunden MJ, Mawdsley J, Bastin AJ, McAuley D, Griffiths M et al (2006) New flow cytometric technique for the evaluation of circulating endothelial progenitor cell levels in various disease groups. J Immunol Methods 316(1–2):107–115. doi: 10.1016/j.jim.2006.08.011 PubMedCrossRefGoogle Scholar
  14. 14.
    George J, Shmilovich H, Deutsch V, Pick M, Miller H, Keren G et al (2006) Comparative analysis of methods for assessment of circulating endothelial progenitor cells. Tissue Eng 12(2):331–335. doi: 10.1089/ten.2006.12.331 PubMedCrossRefGoogle Scholar
  15. 15.
    Allanore Y, Batteux F, Avouac J, Assous N, Weill B, Kahan A (2007) Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol 25(1):60–66PubMedGoogle Scholar
  16. 16.
    Masuda J, Mitsuyama K, Yamasaki H, Takedatsu H, Okamura T, Andoh A et al (2007) Depletion of endothelial progenitor cells in the peripheral blood of patients with ulcerative colitis. Int J Mol Med 19(2):221–228PubMedGoogle Scholar
  17. 17.
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMedGoogle Scholar
  18. 18.
    Anandarajah AP, Ritchlin CT (2004) Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 16(4):338–343. doi :10.1097/01.bor.0000129718.13939.81<PubMedCrossRefGoogle Scholar
  19. 19.
    Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34(3):585–592. doi: 10.1016/j.semarthrit.2004.07.010 PubMedCrossRefGoogle Scholar
  20. 20.
    Westerweel PE, Luijten RK, Hoefer IE, Koomans HA, Derksen RH, Verhaar MC (2007) Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis 66(7):865–870. doi: 10.1136/ard.2006.065631 PubMedCrossRefGoogle Scholar
  21. 21.
    Fadini GP, Agostini C, Sartore S, Avogaro A (2007) Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis 194(1):46–54. doi: 10.1016/j.atherosclerosis.2007.03.046 PubMedCrossRefGoogle Scholar
  22. 22.
    van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE (2006) Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8(5):R151. doi: 10.1186/ar2045 PubMedCrossRefGoogle Scholar
  23. 23.
    Georgiadis AN, Voulgari PV, Argyropoulou MI, Alamanos Y, Elisaf M, Tselepis AD et al (2008) Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 38(1):13–19PubMedCrossRefGoogle Scholar
  24. 24.
    Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172PubMedGoogle Scholar
  25. 25.
    Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y et al (2007) Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 36(4):203–209. doi: 10.1016/j.semarthrit.2006.09.001 PubMedCrossRefGoogle Scholar
  26. 26.
    Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C et al (2007) Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 15(57):287–293. doi: 10.1002/art.22530 CrossRefGoogle Scholar
  27. 27.
    Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Säemann M et al (2007) Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann Rheum Dis 66(10):1284–1288. doi: 10.1136/ard.2006.066605 PubMedCrossRefGoogle Scholar
  28. 28.
    Shantsila E, Watson T, Tse HF, Lip GY (2007) Endothelial colony forming units: are they a reliable marker of endothelial progenitor cell numbers. Ann Med 39(6):474–479. doi: 10.1080/07853890701329283 PubMedCrossRefGoogle Scholar
  29. 29.
    Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA (2007) Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109:1801–1809PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Jacob N. Ablin
    • 1
  • Zacharinka Goldstein
    • 2
  • Valerie Aloush
    • 2
  • Hagit Matz
    • 3
  • Ori Elkayam
    • 2
  • Dan Caspi
    • 1
  • Shmuel Swartzenberg
    • 4
  • Jacob George
    • 4
  • Yonit Wohl
    • 3
  1. 1.The Department of Rheumatology, Rheumatology InstituteTel-Aviv Sourasky Medical CenterTel AvivIsrael
  2. 2.Department of Internal Medicine FTel-Aviv Sourasky Medical CenterTel AvivIsrael
  3. 3.Department of DermatologyTel-Aviv Sourasky Medical CenterTel AvivIsrael
  4. 4.Cardiology InstituteTel-Aviv Sourasky Medical CenterTel AvivIsrael

Personalised recommendations